Horizon Pharma plc to Acquire Crealta Holdings LLC in All Cash Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Mizuho Securities Raises Price Target to $36 Following Horizon Pharma's (HZNP) Announced Crealta Deal
December 14, 2015 8:15 AM ESTMizuho Securities reiterated a Buy rating on Horizon Pharma (NASDAQ: HZNP), and raised the price target to $36.00 (from $34.00), following the Crealta announcement. Horizon plans to acquire Crealta, a private company selling Krystexxa, a third line, Orphan biologic for the treatment of chronic,... More
